Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 16
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Identification of Transgene-Free CRISPR-Edited Plants of Rice, Tomato, and Arabidopsis by Monitoring DsRED Fluorescence in Dry Seeds

  • Aliaga Franco, Norma
  • Zhang, Cunjin
  • Srivastava, Anjil K.
  • Sadanandom, Ari
  • Minguet, E.G.
  • Presa Castro, Silvia
  • GRANELL RICHART, ANTONIO|||0000-0003-4266-9581
  • ALABADÍ DIEGO, DAVID|||0000-0001-8492-6713
  • BLAZQUEZ, MIGUEL-ANGEL|||0000-0001-5743-0448
[EN] Efficient elimination of the editing machinery remains a challenge in plant biotechnology after genome editing to minimize the probability of off-target mutations, but it is also important to deliver end users with edited plants free of foreign DNA. Using the modular cloning system Golden Braid, we have included a fluorescence-dependent transgene monitoring module to the genome-editing tool box. We have tested this approach in Solanum lycopersicum, Oryza sativa, and Arabidopsis thaliana. We demonstrate that DsRED fluorescence visualization works efficiently in dry seeds as marker for the detection of the transgene in the three species allowing an efficient method for selecting transgene-free dry seeds. In the first generation of DsRED-free CRISPR/Cas9 null segregants, we detected gene editing of selected targets including homozygous mutants for the plant species tested. We demonstrate that this strategy allows rapid selection of transgene-free homozygous edited crop plants in a single generation after in vitro transformation., Grants AGL2014-57200-JIN (EGM), BFU2016-80621-P (MB), and BIO2016-78601-R (AG) from the current Spanish Ministry of Science, Innovation and Universities. Grants TRADITOM (634561), TomGEM (679796), Newcotiana (760331-2) and Pharma-Factory (SEP-210417525) from European Union H2020 program (AG). ERC grant "SUMOrice" and BBSRC grant "Flooding tolerance in rice" (AS).
Repositori Obert UdL
Publication Artículo científico (JournalArticle)

Contributions of the international plant science community to the fight against infectious diseases in humans - part 2: endemic and re-emerging diseases

  • He, Wenshu
  • Baysal, Can
  • Lobato, Maria
  • Huang, Xin
  • Alvarez, Derry
  • Zhu, Changfu
  • Armario-Nájera, Victoria
  • Blanco Perera, Amaya
  • Cerda, Pedro
  • Saba-Mayoral, Andrea
  • Sobrino-Mengual, Guillermo
  • Vargheese, Ashwin
  • Abranches, Rita
  • Abreu, Isabel Alexandra
  • Balamurugan, Shanmugaraj
  • Bock, Ralph
  • Buyel, Johannes F.
  • Cunha, Nicolau B. da
  • Daniell, Henry
  • Faller, Roland
  • Folgado, André
  • Gowtham, Iyappan
  • Häkkinen, Suvi
  • Kumar, Shashi
  • Sathish Kumar, Ramalingam
  • Lacorte, Cristiano
  • Lomonossoff, George P.
  • Luís, Ines M.
  • Ma, Julian K-C
  • McDonald, Karen A.
  • Murad, Andre
  • Nandi, Somen
  • O'Keef, Barry
  • Parthiban, Subramanian
  • Paul, Mathew J.
  • Ponndorf, Daniel
  • Rech, Elibio
  • Rodrigues, Julio C. M.
  • Ruf, Stephanie
  • Schillberg, Stefan
  • Schwestka, Jennifer
  • Shah, Priya S.
  • Singh, Rahul
  • Stoger, Eva
  • Twyman, Richard M.
  • Varghese, Inchakalody P.
  • Vianna, Giovanni R.
  • Webster, Gina
  • Wilbers, Ruud H. P.
  • Christou, Paul
  • Oksman-Caldentey, Kirsi-Marja
  • Capell Capell, Teresa
The fight against infectious diseases often focuses on epidemics and pandemics, which demand urgent resources and command attention from the health authorities and media. However, the vast majority of deaths caused by infectious diseases occur in endemic zones, particularly in developing countries, placing a disproportionate burden on underfunded health systems and often requiring international interventions. The provision of vaccines and other biologics is hampered not only by the high cost and limited scalability of traditional manufacturing platforms based on microbial and animal cells, but also by challenges caused by distribution and storage, particularly in regions without a complete cold chain. In this review article, we consider the potential of molecular farming to address the challenges of endemic and re-emerging diseases, focusing on edible plants for the development of oral drugs. Key recent developments in this field include successful clinical trials based on orally delivered dried leaves of Artemisia annua against malarial parasite strains resistant to artemisinin combination therapy, the ability to produce clinical-grade protein drugs in leaves to treat infectious diseases and the long-term storage of protein drugs in dried leaves at ambient temperatures. Recent FDA approval of the first orally delivered protein drug encapsulated in plant cells to treat peanut allergy has opened the door for the development of affordable oral drugs that can be manufactured and distributed in remote areas without cold storage infrastructure and that eliminate the need for expensive purification steps and sterile delivery by injection., The authors would like to thank the Spanish Ministry of Economy, Industry and Competitiveness (project AGL2017-85377-R), the Spanish Ministry of Science, Innovation and Universities (projects RTI2018-097613-B-I00 and PGC2018-097655-B-I00), the EU Horizon 2020 project Pharma-Factory (774078) and the Gener- alitat de Catalunya (Grups Consolidats2017-SGR828); Ag encia de Gesti o d’Ajuts Universitaris i de Recerca (AGAUR), Departament d’Empresa i Coneixement de la Generalitat de Catalunya (PAND EMIES 2020); Project LISBOA-01-0145-FEDER-007660 (Microbiologia Molecular, Estrutural e Celular funded by FEDER funds through COMPETE2020)—Programa Operacional Compet- itividade e Internacionalizacß~ao (POCI) and by the FCT (Portugal) through the R&D Unit, UIDB/04551/2020 (GREEN-IT—Biore- sources for Sustainability); UKIERI and the Hotung Foundation for sustained support of the Bharathiar University / St. George’s Univ. of London collaboration and the Molecular Immunology Unit at St. George’s Univ. of London. The Max Planck Society, the EU Horizon 2020 project Newcotiana (760331-2) and a grant from the European Research Council (ERC-ADG-2014; grant agreement 669982) to RB. KMOC, RMT and STH acknowledge support from the InnCoCells project funded by the European Union’s Horizon 2020 research and innovation programme under grant agreement 101000373. PSS, KAM, RF and SN are partially supported by a CRAFT award (COVID-19 Research Accelerator Funding Track) by the University of California Davis. KAM and SN were partially supported by NASA Space Technology Research (award number NNX17AJ31G) and by the Translational Research Institute through NASA (grant number NNX16AO69A); EMBRAPA (Brazilian Agricultural Corporation), INCT BioSyn (National Institute of Science and Technology in Synthetic Biology), CNPq, CAPES, Brazilian Ministry of Health, FAPDFnd Universidade Cat olica de Bras ılia (UCB), Bras ılia, Brazil; BBSRC Grant BB/L020955/1, the JIC Strategic Programme Grant ‘Molecules from Nature –Enhanced Research Capacity’ (BBS/E/ J/000PR9794), the John Innes Foundation and the Department of Health and Social Care using UK Aid funding managed by the BBSRC; and The Austrian Science Fund FWF (project W1224). TTW Veni Grant 16740 from the Netherlands Organization for Scientific Research. Research in the Daniell laboratory was supported by NIH grants R01 GM 63879, R01 107904, R01 HL 109442, R01 133191 and grants from Bayer, Novo Nordisk and Shire/Takeda. The National Heart Lung and Blood Institute, National Institutes of Health, Department of Health and Human Services, through the Science Moving TowArds Research Trans- lation and Therapy (SMARTT) programme contracts # HHSN268201600014C, HHSN268201600011C supported IND enabling regulatory, toxicology and pharmacokinetic studies. Any opinions, findings and conclusions or recommendations expressed in this material are those of the author (s) and do not necessarily reflect the views of the University of California, Davis, National Aeronautics and Space Administration (NASA) or the Translational Research Institute for Space Health (TRISH). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Views expressed in this article are those of the authors and do not necessarily reflect those of the employing institutions or the UK Department of Health and Social Care
Repositori Obert UdL
Publication Artículo científico (JournalArticle)

The SARS-CoV-2 spike protein receptor-binding domain expressed in rice callus features a homogeneous mix of complex-type glycans

  • Sobrino-Mengual, Guillermo
  • Armario-Najera, Victoria
  • Balieu, Juliette
  • Walet-Balieu, Marie-Laure
  • Saba-Mayoral, Andrea
  • Pelacho Aja, Ana Mª
  • Capell Capell, Teresa
  • Christou, Paul
  • Bardor, Muriel
  • Lerouge, Patrice
The spike protein receptor-binding domain (RBD) of SARS-CoV-2 is required for the infection of human cells. It is the main target that elicits neutralizing antibodies and also a major component of diagnostic kits. The large demand for this protein has led to the use of plants as a production platform. However, it is necessary to determine the N-glycan structures of an RBD to investigate its efficacy and functionality as a vaccine candidate or diagnostic reagent. Here, we analyzed the N-glycan profile of the RBD produced in rice callus. Of the two potential N-glycan acceptor sites, we found that one was not utilized and the other contained a mixture of complex-type N-glycans. This differs from the heterogeneous mixture of N-glycans found when an RBD is expressed in other hosts, including Nicotiana benthamiana. By comparing the glycosylation profiles of different hosts, we can select platforms that produce RBDs with the most beneficial N-glycan structures for different applications., : We acknowledge funding from the Spanish Ministry of Science and Innovation MCIN/AEI/ 10.13039/501100011033/FEDER EU to project PID2022-1414160B-I00 and by Generalitat de Catalunya Grant 2021 SGR 01501 to the Agricultural Biotechnology and Bioeconomy Unit (ABBU). This research was funded by the European Union’s Horizon 2020 Research and Innovation Program through the Pharma-Factory project under Grant No. 774078. This work was also financially supported by the French government through the ANR agency under the ANR PRCE DAGENTA project (ANR-21- CE20-0038-001) and the program «Grand défi Biomédicament: améliorer les rendements et maîtriser les coûts de production: Nouveaux Systèmes d’Expression—2020» (PHAEOMABS project—ANR-21- F2II-0005). We acknowledge the Spanish Ministry of Science, Innovation and Universities for their FPI fellowship PRE2019-088852 given to GSM.
Repositori Obert UdL
Publication Artículo científico (JournalArticle)

Contributions of the international plant science community to the fight against infectious diseases in humans - part 1: epidemic and pandemic diseases, including HIV/AIDS and coronaviruses

  • Lobato, Maria
  • Huang, Xin
  • Alvarez, Derry
  • He, Wenshu
  • Baysal, Can
  • Zhu, Changfu
  • Armario-Nájera, Victoria
  • Blanco Perera, Amaya
  • Cerda, Pedro
  • Saba-Mayoral, Andrea
  • Sobrino-Mengual, Guillermo
  • Vargheese, Ashwin
  • Abranches, Rita
  • Abreu, Isabel Alexandra
  • Balamurugan, Shanmugaraj
  • Bock, Ralph
  • Buyel, Johannes F.
  • Cunha, Nicolau B. da
  • Daniell, Henry
  • Faller, Roland
  • Folgado, André
  • Gowtham, Iyappan
  • Häkkinen, Suvi
  • Kumar, Shashi
  • Sathish Kumar, Ramalingam
  • Lacorte, Cristiano
  • Lomonossoff, George P.
  • Luís, Ines M.
  • Ma, Julian K-C
  • McDonald, Karen A.
  • Murad, Andre
  • Nandi, Somen
  • O'Keef, Barry
  • Oksman-Caldentey, Kirsi-Marja
  • Parthiban, Subramanian
  • Paul, Mathew J.
  • Ponndorf, Daniel
  • Rech, Elibio
  • Rodrigues, Julio C. M.
  • Ruf, Stephanie
  • Schillberg, Stefan
  • Schwestka, Jennifer
  • Shah, Priya S.
  • Singh, Rahul
  • Stoger, Eva
  • Twyman, Richard M.
  • Varghese, Inchakalody P.
  • Vianna, Giovanni R.
  • Webster, Gina
  • Wilbers, Ruud H. P.
  • Capell Capell, Teresa
  • Christou, Paul
Infectious diseases, also known as transmissible or communicable diseases, are caused by pathogens or parasites that spread in communities by direct contact with infected individuals or contaminated materials, through droplets and aerosols, or via vectors such as insects. Such diseases cause 17% of all human deaths and their management and control places an immense burden on healthcare systems worldwide. Traditional approaches for the prevention and control of infectious diseases include vaccination programmes, hygiene measures and drugs that suppress the pathogen, treat the disease symptoms or attenuate aggressive reactions of the host immune system. The provision of vaccines and biologic drugs such as antibodies is hampered by the high cost and limited scalability of traditional manufacturing platforms based on microbial and animal cells, particularly in developing countries where infectious diseases are prevalent and poorly controlled. Molecular farming, which uses plants for protein expression, is a promising strategy to address the drawbacks of current manufacturing platforms. In this review article, we consider the potential of molecular farming to address healthcare demands for the most prevalent and important epidemic and pandemic diseases, focussing on recent outbreaks of high-mortality coronavirus infections and diseases that disproportionately affect the developing world., The authors would like to thank the Spanish Ministry of Economy, Industry and Competitiveness (project AGL2017-85377-R), the Spanish Ministry of Science, Innovation and Universities (projects RTI2018-097613-B-I00 and PGC2018-097655-B-I00), the EU Horizon 2020 project Pharma-Factory (774078) and the Gener- alitat de Catalunya (Grups Consolidats 2017-SGR828), Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR), Departa- ment d’Empresa i Coneixement de la Generalitat de Catalunya (PAND EMIES 2020). Project LISBOA-01-0145-FEDER-007660 (Microbiologia Molecular, Estrutural e Celular funded by FEDER funds through COMPETE2020 –Programa Operacional Compet- itividade e Internacionalizacß~ao (POCI) and by the FCT (Portugal) through the R&D Unit, UIDB/04551/2020 (GREEN-IT –Biore- sources for Sustainability). UKIERI and the Hotung Foundation for sustained support of the Bharathiar University / St. George’s Univ. of London collaboration and the Molecular Immunology Unit at St. George’s Univ of London. The Max Planck Society, the EU Horizon 2020 project Newcotiana, 760331-2) and a grant from the European Research Council (ERC-ADG-2014; grant agree- ment 669982) to RB. KMOC, RMT and STH acknowledge support from the InnCoCells project funded by the European Union’s Horizon 2020 research and innovation programme under grant agreement 101000373. PSS, KAM, RF, and SN are partially supported by a CRAFT award (COVID-19 Research Accelerator Funding Track) by the University of California Davis. KAM and SN were partially supported by NASA Space Technology Research (award number NNX17AJ31G) and by the Translational Research Institute through NASA (grant number NNX16AO69A). EMBRAPA (Brazilian Agricultural Corporation), INCT BioSyn (National Institute of Science and Technology in Synthetic Biology), CNPq, CAPES, Brazilian Ministry of Health, FAPDF and Universidade Cat olica de Bras ılia (UCB), Bras ılia, Brazil. BBSRC Grant BB/L020955/1, the JIC Strategic Programme Grant ‘Molecules from Nature –Enhanced Research Capacity’ (BBS/E/ J/000PR9794), the John Innes Foundation and the Department of Health and Social Care using UK Aid funding managed by the BBSRC. The Austrian Science Fund FWF (project W1224). TTW Veni Grant 16740 from the Netherlands Organization for Scientific Research. Research in the Daniell laboratory was supported by NIH grants R01 GM 63879, R01 107904, R01 HL 109442, R01 133191 and grants from Bayer, Novo Nordisk and Shire/Takeda. The National Heart Lung and Blood Institute, National Institutes of Health, Department of Healthand Human Services, through the Science Moving TowArds Research Trans- lation and Therapy (SMARTT) program contracts # HHSN268201600014C, HHSN268201600011C supported IND enabling regulatory, toxicology and pharmacokinetic studies. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author (s) and do not necessarily reflect the views of the University of California, Davis, National Aeronautics and Space Administration (NASA) or the Translational Research Institute for Space Health (TRISH). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Views expressed in this article are those of the authors and do not necessarily reflect those of the employing institutions or the UK Department of Health and Social Care.
Repositori Obert UdL
Publication Artículo científico (JournalArticle)

Performance of plant-produced RBDs as SARS-CoV-2 diagnostic reagents: a tale of two plant platforms

  • Santoni, Mattia
  • Gutierrez-Valdes, Noemi
  • Pivotto, Denise
  • Zanichelli, Elena
  • Rosa, Anthony
  • Sobrino-Mengual, Guillermo
  • Balieu, Juliette
  • Lerouge, Patrice
  • Bardor, Muriel
  • Cecchetto, Riccardo
  • Compri, Monica
  • Mazzariol, Annarita
  • Ritala, Anneli
  • Avesani, Linda
The COVID-19 pandemic has underscored the need for rapid and cost-effective diagnostic tools. Serological tests, particularly those measuring antibodies targeting the receptor-binding domain (RBD) of the virus, play a pivotal role in tracking infection dynamics and vaccine effectiveness. In this study, we aimed to develop a simple enzyme-linked immunosorbent assay (ELISA) for measuring RBD-specific antibodies, comparing two plant-based platforms for diagnostic reagent production. We chose to retain RBD in the endoplasmic reticulum (ER) to prevent potential immunoreactivity issues associated with plant-specific glycans. We produced ER-retained RBD in two plant systems: a stable transformation of BY-2 plant cell culture (BY2-RBD) and a transient transformation in Nicotiana benthamiana using the MagnICON system (NB-RBD). Both systems demonstrated their suitability, with varying yields and production timelines. The plant-made proteins revealed unexpected differences in N-glycan profiles, with BY2-RBD displaying oligo-mannosidic N-glycans and NB-RBD exhibiting a more complex glycan profile. This difference may be attributed to higher recombinant protein synthesis in the N. benthamiana system, potentially overloading the ER retention signal, causing some proteins to traffic to the Golgi apparatus. When used as diagnostic reagents in ELISA, BY2-RBD outperformed NB-RBD in terms of sensitivity, specificity, and correlation with a commercial kit. This discrepancy may be due to the distinct glycan profiles, as complex glycans on NB-RBD may impact immunoreactivity. In conclusion, our study highlights the potential of plant-based systems for rapid diagnostic reagent production during emergencies. However, transient expression systems, while offering shorter timelines, introduce higher heterogeneity in recombinant protein forms, necessitating careful consideration in serological test development., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work has been performed in the context of the “European Union’s Horizon 2020 Research and Innovation Programme” under Grant Agreement 774078 Pharma Factory project ( https://pharmafactory.org/ ). GS-M acknowledges the Spanish Ministry of Science, Innovation, and Universities for FPI fellowship PRE2019-088852. The authors acknowledge the University of Rouen Normandie and the ANR PhaeomAbs PIA Grand défi Biomédicaments for its financial support. Dr. Marie-Laure Walet-Balieu from Université de Rouen Normandie, INSERM US 51, CNRS UAR 2026, HeRacLeS-PISSARO, F-76000 Rouen, France, is acknowledged for technical help with the injections in LC-ESI MS MS. HeRacLeS PISSARO Proteomics Platform was supported by Rouen University, INSERM, Normandy Region and the European Union. Europe gets involved in Normandy with European Regional Development Fund (ERDF). We thank the excellent technical assistance of Jaana Rikkinen and Kaisa Rinta-Harri at VTT.
Repositori Obert UdL
Publication Artículo científico (JournalArticle)

Unexpected synergistic HIV neutralization by a triple microbicide produced in rice endosperm

  • Vamvaka, Evangelia
  • Farré Martinez, Gemma
  • Molinos-Albert, Luis M.
  • Evans, Abbey
  • Canela Xandri, Anna
  • Twyman, Richard M.
  • Carrillo, Jorge
  • Ordóñez, Raziel Antonio
  • Shattock, Robin J.
  • O’Keef, Barry R.
  • Clotet, Bonaventura
  • Blanco, Julian
  • Khush, Gurdev S.
  • Christou, Paul
  • Capell Capell, Teresa
The transmission of HIV can be prevented by the application of neutralizing monoclonal antibodies and lectins. Traditional recombinant protein manufacturing platforms lack sufficient capacity and are too expensive for developing countries, which suffer the greatest disease burden. Plants offer an inexpensive and scalable alternative manufacturing platform that can produce multiple components in a single plant, which is important because multiple components are required to avoid the rapid emergence of HIV-1 strains resistant to single microbicides. Furthermore, crude extracts can be used directly for prophylaxis to avoid the massive costs of downstream processing and purification. We investigated whether rice could simultaneously produce three functional HIV-neutralizing proteins (the monoclonal antibody 2G12, and the lectins griffithsin and cyanovirin-N). Preliminary in vitro tests showed that the cocktail of three proteins bound to gp120 and achieved HIV-1 neutralization. Remarkably, when we mixed the components with crude extracts of wild-type rice endosperm, we observed enhanced binding to gp120 in vitro and synergistic neutralization when all three components were present. Extracts of transgenic plants expressing all three proteins also showed enhanced in vitro binding to gp120 and synergistic HIV-1 neutralization. Fractionation of the rice extracts suggested that the enhanced gp120 binding was dependent on rice proteins, primarily the globulin fraction. Therefore, the production of HIV-1 microbicides in rice may not only reduce costs compared to traditional platforms but may also provide functional benefits in terms of microbicidal potency., We thank Ms. Jennifer Wilson for technical assistance with live-virus anti-HIV assays. We received funding from Spanish Ministry of Science and Innovation Grant BIO2014-54426-P; Spanish Ministry of Economy, Industry and Competitiveness Grant AGL2017-85377-R; the European Fund for Economic and Regional Development; Generalitat de Catalunya Grant 2017 SGR 828 to the Agricultural Biotechnology and Bioeconomy Unit; and European Union Farma-Factory Grant Agreement 774078, H2020-BB-2016-2017/H2020-BB-2017-1. This project was funded in whole or in part with federal funds from the National Cancer Institute (NCI), NIH, under Contract HHSN26120080001E and was supported in part by the Intramural Research Program of the NIH, NCI, Center for Cancer Research, and Instituto de Salud Carlos III project PI14/01307. The EVA648 W61D and gp120 0607 IIIB were provided by the Medical Research Center Centralized Facility for AIDS reagents. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does the mention of trade names, commercial products, or organizations imply endorsement by the US government.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Otros (Other)

Pilot production of SARS-CoV-2 related proteins in plants: a proof of concept for rapid repurposing of indoors farms into biomanufacturing facilities

  • Diego-Martin, Borja
  • González, Beatriz
  • Vázquez-Vilar, Marta
  • Selma, Sara
  • Mateos-Fernández, Rubén
  • Gianoglio, Silvia
  • Fernández-del-Carmen, Asun
  • Orzáez, Diego
The current CoVid-19 crisis is revealing the strengths and the weaknesses of the world's capacity to respond to a global health crisis. A critical weakness has resulted from the excessive centralization of the current biomanufacturing capacities, a matter of great concern, if not a source of nationalistic tensions. On the positive side, scientific data and information have been shared at an unprecedented speed fuelled by the preprint phenomena, and this has considerably strengthened our ability to develop new technology-based solutions. In this work we explore how, in a context of rapid exchange of scientific information, plant biofactories can serve as a rapid and easily adaptable solution for local manufacturing of bioreagents, more specifically recombinant antibodies. For this purpose, we tested our ability to produce, in the framework of an academic lab and in a matter of weeks, milligram amounts of six different recombinant monoclonal antibodies against SARS-CoV-2 in Nicotiana benthamiana. For the design of the antibodies we took advantage, among other data sources, of the DNA sequence information made rapidly available by other groups in preprint publications. mAbs were all engineered as single-chain fragments fused to a human gamma Fc and transiently expressed using a viral vector. In parallel, we also produced the recombinant SARS-CoV-2 N protein and its Receptor Binding Domain (RBD) in planta and used them to test the binding specificity of the recombinant mAbs. Finally, for two of the antibodies we assayed a simple scale-up production protocol based on the extraction of apoplastic fluid. Our results indicate that gram amounts of anti-SARS-CoV-2 antibodies could be easily produced in little more than 6 weeks in repurposed greenhouses with little infrastructure requirements using N. benthamiana as production platform. Similar procedures could be easily deployed to produce diagnostic reagents and, eventually, could be adapted for rapid therapeutic responses., This work was supported by H2020 EU projects 760331 Newcotiana and 774078 PharmaFactory. S.S. is recipient of a FPI fellowship BIO2016‐78601‐R from the Spanish Ministry of Science and Competitiveness and R.M. is recipient of a GVA fellowship (ACIF/2019/226)., No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Pilot Production of SARS-CoV-2 Related Proteins in Plants: A Proof of Concept for Rapid Repurposing of Indoor Farms Into Biomanufacturing Facilities

  • Diego-Martin, Borja
  • González, Beatriz
  • Vázquez-Vilar, Marta
  • Selma, Sara
  • Mateos-Fernández, Rubén
  • Gianoglio, Silvia
  • Fernández-del-Carmen, Asun
  • Orzáez, Diego
Disponible también versión preprint: http://hdl.handle.net/10261/221118, The current CoVid-19 crisis is revealing the strengths and the weaknesses of the world’s capacity to respond to a global health crisis. A critical weakness has resulted from the excessive centralization of the current biomanufacturing capacities, a matter of great concern, if not a source of nationalistic tensions. On the positive side, scientific data and information have been shared at an unprecedented speed fuelled by the preprint phenomena, and this has considerably strengthened our ability to develop new technology-based solutions. In this work, we explore how, in a context of rapid exchange of scientific information, plant biofactories can serve as a rapid and easily adaptable solution for local manufacturing of bioreagents, more specifically recombinant antibodies. For this purpose, we tested our ability to produce, in the framework of an academic lab and in a matter of weeks, milligram amounts of six different recombinant monoclonal antibodies against SARS-CoV-2 in Nicotiana benthamiana. For the design of the antibodies, we took advantage, among other data sources, of the DNA sequence information made rapidly available by other groups in preprint publications. mAbs were engineered as single-chain fragments fused to a human gamma Fc and transiently expressed using a viral vector. In parallel, we also produced the recombinant SARS-CoV-2 N protein and the receptor binding domain (RBD) of the Spike protein in planta and used them to test the binding specificity of the recombinant mAbs. Finally, for two of the antibodies, we assayed a simple scale-up production protocol based on the extraction of apoplastic fluid. Our results indicate that gram amounts of anti-SARS-CoV-2 antibodies could be easily produced in little more than 6 weeks in repurposed greenhouses with little infrastructure requirements using N. benthamiana as production platform. Similar procedures could be easily deployed to produce diagnostic reagents and, eventually, could be adapted for rapid therapeutic responses., This work was supported by H2020 EU projects 760331 Newcotiana and 774078 PharmaFactory. SS is recipient of a FPI fellowship BIO2016–78601-R from the Spanish Ministry of Science and Competitiveness and RM-F is recipient of a GVA fellowship (ACIF/2019/226)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A replicating viral vector greatly enhances accumulation of helical virus-like particles in plants

  • Thuenemann, Eva C.
  • Byrne, Matthew J.
  • Peyret, Hadrien
  • Saunders, Keith
  • Castells Graells, Roger
  • Ferriol, Inmaculada
  • Santoni, Mattia
  • Steele, John F. C.
  • Ranson, Neil A.
  • Avesani, Linda
  • López-Moya Gómez, Juan José
  • Lomonossoff, George P.
This article belongs to the Section Viruses of Plants, Fungi and Protozo., The production of plant helical virus-like particles (VLPs) via plant-based expression has been problematic with previous studies suggesting that an RNA scaffold may be necessary for their efficient production. To examine this, we compared the accumulation of VLPs from two potexviruses, papaya mosaic virus and alternanthera mosaic virus (AltMV), when the coat proteins were expressed from a replicating potato virus X- based vector (pEff) and a non-replicating vector (pEAQ-HT). Significantly greater quantities of VLPs could be purified when pEff was used. The pEff system was also very efficient at producing VLPs of helical viruses from different virus families. Examination of the RNA content of AltMV and tobacco mosaic virus VLPs produced from pEff revealed the presence of vector-derived RNA sequences, suggesting that the replicating RNA acts as a scaffold for VLP assembly. Cryo-EM analysis of the AltMV VLPs showed they had a structure very similar to that of authentic potexvirus particles. Thus, we conclude that vectors generating replicating forms of RNA, such as pEff, are very efficient for producing helical VLPs, This work was supported by the EC Horizon 2020 project Pharma-Factory (774078). At JIC, this work was also supported by the UK Biotechnology and Biological Sciences Research Council (BBSRC) Grants BB/R001669/1 and BB/T004703/1, the Institute Strategic Programme Grant “Molecules from Nature—Enhanced Research Capacity” (BBS/E/J/000PR9794), and the John Innes Foundation. Work at CRAG was supported by grant PID2019-105692RB-100 and “Severo Ochoa Programme for Centres of Excellence in R&D” SEV-2015-0533 and CEX2019-000902-S from the Spanish Ministry of Science and Innovation, and from the Generalitat de Catalunya CERCA Institution. I.F. performed a stay in JIC financed by BBSRC through a Flexibility talent mobility grant (FTMA) in the frame of a JIC-CRAG secondment program (CA759C05B)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

CryoEM and stability analysis of virus-like particles of potyvirus and ipomovirus infecting a common host

  • Chase, Ornela
  • Javed, Abid
  • Byrne, Matthew J.
  • Thuenemann, Eva C.
  • Lomonossoff, George P.
  • Ranson, Neil A.
  • López-Moya Gómez, Juan José
Sweet potato feathery mottle virus (SPFMV) and Sweet potato mild mottle virus (SPMMV) are members of the genera Potyvirus and Ipomovirus, family Potyviridae, sharing Ipomoea batatas as common host, but transmitted, respectively, by aphids and whiteflies. Virions of family members consist of flexuous rods with multiple copies of a single coat protein (CP) surrounding the RNA genome. Here we report the generation of virus-like particles (VLPs) by transient expression of the CPs of SPFMV and SPMMV in the presence of a replicating RNA in Nicotiana benthamiana. Analysis of the purified VLPs by cryo-electron microscopy, gave structures with resolutions of 2.6 and 3.0 Å, respectively, showing a similar left-handed helical arrangement of 8.8 CP subunits per turn with the C-terminus at the inner surface and a binding pocket for the encapsidated ssRNA. Despite their similar architecture, thermal stability studies reveal that SPMMV VLPs are more stable than those of SPFMV., Funding provided by grant PID2019-105692RB-100 (to J.J.L.M.) and CEX2019-000902-S (awarded to CRAG), both from Agencia Estatal de Investigación AEI, Spain, MCIN/AEI/10.13039/501100011033, by CERCA Programme / Generalitat de Catalunya grant 2018 FI_B 00329 and EMBO Short-Term Fellowship 8695 (to O.C.), by EC Horizon 2020 project Pharma-Factory 774078, and UK Biotechnology and Biological Sciences Research Council (BBSRC) Grants BB/R001669/1 and BB/T004703/1 (to G.P.L.), and BB/T004525/1 (to N.A.R. and G.P.L.), and by Institute Strategic Programme Grant “Molecules from Nature—Enhanced Research Capacity” BBS/E/J/000PR9794 and the John Innes Foundation., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2019-000902-S), Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Contributions of the international plant science community to the fight against infectious diseases in humans - part 2: endemic and re-emerging diseases

  • He, Wenshu
  • Baysal, Can
  • Lobato, Maria
  • Huang, Xin
  • Alvarez, Derry
  • Zhu, Changfu
  • Armario-Nájera, Victoria
  • Blanco Perera, Amaya
  • Cerda, Pedro
  • Saba-Mayoral, Andrea
  • Sobrino-Mengual, Guillermo
  • Vargheese, Ashwin
  • Abranches, Rita
  • Abreu, Isabel Alexandra
  • Balamurugan, Shanmugaraj
  • Bock, Ralph
  • Buyel, Johannes F.
  • Cunha, Nicolau B. da
  • Daniell, Henry
  • Faller, Roland
  • Folgado, André
  • Gowtham, Iyappan
  • Häkkinen, Suvi
  • Kumar, Shashi
  • Sathish Kumar, Ramalingam
  • Lacorte, Cristiano
  • Lomonossoff, George P.
  • Luís, Ines M.
  • Ma, Julian K-C
  • McDonald, Karen A.
  • Murad, Andre
  • Nandi, Somen
  • O'Keef, Barry
  • Parthiban, Subramanian
  • Paul, Mathew J.
  • Ponndorf, Daniel
  • Rech, Elibio
  • Rodrigues, Julio C. M.
  • Ruf, Stephanie
  • Schillberg, Stefan
  • Schwestka, Jennifer
  • Shah, Priya S.
  • Singh, Rahul
  • Stoger, Eva
  • Twyman, Richard M.
  • Varghese, Inchakalody P.
  • Vianna, Giovanni R.
  • Webster, Gina
  • Wilbers, Ruud H. P.
  • Christou, Paul
  • Oksman-Caldentey, Kirsi-Marja
  • Capell Capell, Teresa
The fight against infectious diseases often focuses on epidemics and pandemics, which demand urgent resources and command attention from the health authorities and media. However, the vast majority of deaths caused by infectious diseases occur in endemic zones, particularly in developing countries, placing a disproportionate burden on underfunded health systems and often requiring international interventions. The provision of vaccines and other biologics is hampered not only by the high cost and limited scalability of traditional manufacturing platforms based on microbial and animal cells, but also by challenges caused by distribution and storage, particularly in regions without a complete cold chain. In this review article, we consider the potential of molecular farming to address the challenges of endemic and re-emerging diseases, focusing on edible plants for the development of oral drugs. Key recent developments in this field include successful clinical trials based on orally delivered dried leaves of Artemisia annua against malarial parasite strains resistant to artemisinin combination therapy, the ability to produce clinical-grade protein drugs in leaves to treat infectious diseases and the long-term storage of protein drugs in dried leaves at ambient temperatures. Recent FDA approval of the first orally delivered protein drug encapsulated in plant cells to treat peanut allergy has opened the door for the development of affordable oral drugs that can be manufactured and distributed in remote areas without cold storage infrastructure and that eliminate the need for expensive purification steps and sterile delivery by injection., The authors would like to thank the Spanish Ministry of Economy, Industry and Competitiveness (project AGL2017-85377-R), the Spanish Ministry of Science, Innovation and Universities (projects RTI2018-097613-B-I00 and PGC2018-097655-B-I00), the EU Horizon 2020 project Pharma-Factory (774078) and the Gener- alitat de Catalunya (Grups Consolidats2017-SGR828); Ag encia de Gesti o d’Ajuts Universitaris i de Recerca (AGAUR), Departament d’Empresa i Coneixement de la Generalitat de Catalunya (PAND EMIES 2020); Project LISBOA-01-0145-FEDER-007660 (Microbiologia Molecular, Estrutural e Celular funded by FEDER funds through COMPETE2020)—Programa Operacional Compet- itividade e Internacionalizacß~ao (POCI) and by the FCT (Portugal) through the R&D Unit, UIDB/04551/2020 (GREEN-IT—Biore- sources for Sustainability); UKIERI and the Hotung Foundation for sustained support of the Bharathiar University / St. George’s Univ. of London collaboration and the Molecular Immunology Unit at St. George’s Univ. of London. The Max Planck Society, the EU Horizon 2020 project Newcotiana (760331-2) and a grant from the European Research Council (ERC-ADG-2014; grant agreement 669982) to RB. KMOC, RMT and STH acknowledge support from the InnCoCells project funded by the European Union’s Horizon 2020 research and innovation programme under grant agreement 101000373. PSS, KAM, RF and SN are partially supported by a CRAFT award (COVID-19 Research Accelerator Funding Track) by the University of California Davis. KAM and SN were partially supported by NASA Space Technology Research (award number NNX17AJ31G) and by the Translational Research Institute through NASA (grant number NNX16AO69A); EMBRAPA (Brazilian Agricultural Corporation), INCT BioSyn (National Institute of Science and Technology in Synthetic Biology), CNPq, CAPES, Brazilian Ministry of Health, FAPDFnd Universidade Cat olica de Bras ılia (UCB), Bras ılia, Brazil; BBSRC Grant BB/L020955/1, the JIC Strategic Programme Grant ‘Molecules from Nature –Enhanced Research Capacity’ (BBS/E/ J/000PR9794), the John Innes Foundation and the Department of Health and Social Care using UK Aid funding managed by the BBSRC; and The Austrian Science Fund FWF (project W1224). TTW Veni Grant 16740 from the Netherlands Organization for Scientific Research. Research in the Daniell laboratory was supported by NIH grants R01 GM 63879, R01 107904, R01 HL 109442, R01 133191 and grants from Bayer, Novo Nordisk and Shire/Takeda. The National Heart Lung and Blood Institute, National Institutes of Health, Department of Health and Human Services, through the Science Moving TowArds Research Trans- lation and Therapy (SMARTT) programme contracts # HHSN268201600014C, HHSN268201600011C supported IND enabling regulatory, toxicology and pharmacokinetic studies. Any opinions, findings and conclusions or recommendations expressed in this material are those of the author (s) and do not necessarily reflect the views of the University of California, Davis, National Aeronautics and Space Administration (NASA) or the Translational Research Institute for Space Health (TRISH). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Views expressed in this article are those of the authors and do not necessarily reflect those of the employing institutions or the UK Department of Health and Social Care
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Contributions of the international plant science community to the fight against infectious diseases in humans - part 1: epidemic and pandemic diseases, including HIV/AIDS and coronaviruses

  • Lobato, Maria
  • Huang, Xin
  • Alvarez, Derry
  • He, Wenshu
  • Baysal, Can
  • Zhu, Changfu
  • Armario-Nájera, Victoria
  • Blanco Perera, Amaya
  • Cerda, Pedro
  • Saba-Mayoral, Andrea
  • Sobrino-Mengual, Guillermo
  • Vargheese, Ashwin
  • Abranches, Rita
  • Abreu, Isabel Alexandra
  • Balamurugan, Shanmugaraj
  • Bock, Ralph
  • Buyel, Johannes F.
  • Cunha, Nicolau B. da
  • Daniell, Henry
  • Faller, Roland
  • Folgado, André
  • Gowtham, Iyappan
  • Häkkinen, Suvi
  • Kumar, Shashi
  • Sathish Kumar, Ramalingam
  • Lacorte, Cristiano
  • Lomonossoff, George P.
  • Luís, Ines M.
  • Ma, Julian K-C
  • McDonald, Karen A.
  • Murad, Andre
  • Nandi, Somen
  • O'Keef, Barry
  • Oksman-Caldentey, Kirsi-Marja
  • Parthiban, Subramanian
  • Paul, Mathew J.
  • Ponndorf, Daniel
  • Rech, Elibio
  • Rodrigues, Julio C. M.
  • Ruf, Stephanie
  • Schillberg, Stefan
  • Schwestka, Jennifer
  • Shah, Priya S.
  • Singh, Rahul
  • Stoger, Eva
  • Twyman, Richard M.
  • Varghese, Inchakalody P.
  • Vianna, Giovanni R.
  • Webster, Gina
  • Wilbers, Ruud H. P.
  • Capell Capell, Teresa
  • Christou, Paul
Infectious diseases, also known as transmissible or communicable diseases, are caused by pathogens or parasites that spread in communities by direct contact with infected individuals or contaminated materials, through droplets and aerosols, or via vectors such as insects. Such diseases cause 17% of all human deaths and their management and control places an immense burden on healthcare systems worldwide. Traditional approaches for the prevention and control of infectious diseases include vaccination programmes, hygiene measures and drugs that suppress the pathogen, treat the disease symptoms or attenuate aggressive reactions of the host immune system. The provision of vaccines and biologic drugs such as antibodies is hampered by the high cost and limited scalability of traditional manufacturing platforms based on microbial and animal cells, particularly in developing countries where infectious diseases are prevalent and poorly controlled. Molecular farming, which uses plants for protein expression, is a promising strategy to address the drawbacks of current manufacturing platforms. In this review article, we consider the potential of molecular farming to address healthcare demands for the most prevalent and important epidemic and pandemic diseases, focussing on recent outbreaks of high-mortality coronavirus infections and diseases that disproportionately affect the developing world., The authors would like to thank the Spanish Ministry of Economy, Industry and Competitiveness (project AGL2017-85377-R), the Spanish Ministry of Science, Innovation and Universities (projects RTI2018-097613-B-I00 and PGC2018-097655-B-I00), the EU Horizon 2020 project Pharma-Factory (774078) and the Gener- alitat de Catalunya (Grups Consolidats 2017-SGR828), Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR), Departa- ment d’Empresa i Coneixement de la Generalitat de Catalunya (PAND EMIES 2020). Project LISBOA-01-0145-FEDER-007660 (Microbiologia Molecular, Estrutural e Celular funded by FEDER funds through COMPETE2020 –Programa Operacional Compet- itividade e Internacionalizacß~ao (POCI) and by the FCT (Portugal) through the R&D Unit, UIDB/04551/2020 (GREEN-IT –Biore- sources for Sustainability). UKIERI and the Hotung Foundation for sustained support of the Bharathiar University / St. George’s Univ. of London collaboration and the Molecular Immunology Unit at St. George’s Univ of London. The Max Planck Society, the EU Horizon 2020 project Newcotiana, 760331-2) and a grant from the European Research Council (ERC-ADG-2014; grant agree- ment 669982) to RB. KMOC, RMT and STH acknowledge support from the InnCoCells project funded by the European Union’s Horizon 2020 research and innovation programme under grant agreement 101000373. PSS, KAM, RF, and SN are partially supported by a CRAFT award (COVID-19 Research Accelerator Funding Track) by the University of California Davis. KAM and SN were partially supported by NASA Space Technology Research (award number NNX17AJ31G) and by the Translational Research Institute through NASA (grant number NNX16AO69A). EMBRAPA (Brazilian Agricultural Corporation), INCT BioSyn (National Institute of Science and Technology in Synthetic Biology), CNPq, CAPES, Brazilian Ministry of Health, FAPDF and Universidade Cat olica de Bras ılia (UCB), Bras ılia, Brazil. BBSRC Grant BB/L020955/1, the JIC Strategic Programme Grant ‘Molecules from Nature –Enhanced Research Capacity’ (BBS/E/ J/000PR9794), the John Innes Foundation and the Department of Health and Social Care using UK Aid funding managed by the BBSRC. The Austrian Science Fund FWF (project W1224). TTW Veni Grant 16740 from the Netherlands Organization for Scientific Research. Research in the Daniell laboratory was supported by NIH grants R01 GM 63879, R01 107904, R01 HL 109442, R01 133191 and grants from Bayer, Novo Nordisk and Shire/Takeda. The National Heart Lung and Blood Institute, National Institutes of Health, Department of Healthand Human Services, through the Science Moving TowArds Research Trans- lation and Therapy (SMARTT) program contracts # HHSN268201600014C, HHSN268201600011C supported IND enabling regulatory, toxicology and pharmacokinetic studies. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author (s) and do not necessarily reflect the views of the University of California, Davis, National Aeronautics and Space Administration (NASA) or the Translational Research Institute for Space Health (TRISH). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Views expressed in this article are those of the authors and do not necessarily reflect those of the employing institutions or the UK Department of Health and Social Care.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The SARS-CoV-2 spike protein receptor-binding domain expressed in rice callus features a homogeneous mix of complex-type glycans

  • Sobrino-Mengual, Guillermo
  • Armario-Najera, Victoria
  • Balieu, Juliette
  • Walet-Balieu, Marie-Laure
  • Saba-Mayoral, Andrea
  • Pelacho Aja, Ana Mª
  • Capell Capell, Teresa
  • Christou, Paul
  • Bardor, Muriel
  • Lerouge, Patrice
The spike protein receptor-binding domain (RBD) of SARS-CoV-2 is required for the infection of human cells. It is the main target that elicits neutralizing antibodies and also a major component of diagnostic kits. The large demand for this protein has led to the use of plants as a production platform. However, it is necessary to determine the N-glycan structures of an RBD to investigate its efficacy and functionality as a vaccine candidate or diagnostic reagent. Here, we analyzed the N-glycan profile of the RBD produced in rice callus. Of the two potential N-glycan acceptor sites, we found that one was not utilized and the other contained a mixture of complex-type N-glycans. This differs from the heterogeneous mixture of N-glycans found when an RBD is expressed in other hosts, including Nicotiana benthamiana. By comparing the glycosylation profiles of different hosts, we can select platforms that produce RBDs with the most beneficial N-glycan structures for different applications., : We acknowledge funding from the Spanish Ministry of Science and Innovation MCIN/AEI/ 10.13039/501100011033/FEDER EU to project PID2022-1414160B-I00 and by Generalitat de Catalunya Grant 2021 SGR 01501 to the Agricultural Biotechnology and Bioeconomy Unit (ABBU). This research was funded by the European Union’s Horizon 2020 Research and Innovation Program through the Pharma-Factory project under Grant No. 774078. This work was also financially supported by the French government through the ANR agency under the ANR PRCE DAGENTA project (ANR-21- CE20-0038-001) and the program «Grand défi Biomédicament: améliorer les rendements et maîtriser les coûts de production: Nouveaux Systèmes d’Expression—2020» (PHAEOMABS project—ANR-21- F2II-0005). We acknowledge the Spanish Ministry of Science, Innovation and Universities for their FPI fellowship PRE2019-088852 given to GSM.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Performance of plant-produced RBDs as SARS-CoV-2 diagnostic reagents: a tale of two plant platforms

  • Santoni, Mattia
  • Gutierrez-Valdes, Noemi
  • Pivotto, Denise
  • Zanichelli, Elena
  • Rosa, Anthony
  • Sobrino-Mengual, Guillermo
  • Balieu, Juliette
  • Lerouge, Patrice
  • Bardor, Muriel
  • Cecchetto, Riccardo
  • Compri, Monica
  • Mazzariol, Annarita
  • Ritala, Anneli
  • Avesani, Linda
The COVID-19 pandemic has underscored the need for rapid and cost-effective diagnostic tools. Serological tests, particularly those measuring antibodies targeting the receptor-binding domain (RBD) of the virus, play a pivotal role in tracking infection dynamics and vaccine effectiveness. In this study, we aimed to develop a simple enzyme-linked immunosorbent assay (ELISA) for measuring RBD-specific antibodies, comparing two plant-based platforms for diagnostic reagent production. We chose to retain RBD in the endoplasmic reticulum (ER) to prevent potential immunoreactivity issues associated with plant-specific glycans. We produced ER-retained RBD in two plant systems: a stable transformation of BY-2 plant cell culture (BY2-RBD) and a transient transformation in Nicotiana benthamiana using the MagnICON system (NB-RBD). Both systems demonstrated their suitability, with varying yields and production timelines. The plant-made proteins revealed unexpected differences in N-glycan profiles, with BY2-RBD displaying oligo-mannosidic N-glycans and NB-RBD exhibiting a more complex glycan profile. This difference may be attributed to higher recombinant protein synthesis in the N. benthamiana system, potentially overloading the ER retention signal, causing some proteins to traffic to the Golgi apparatus. When used as diagnostic reagents in ELISA, BY2-RBD outperformed NB-RBD in terms of sensitivity, specificity, and correlation with a commercial kit. This discrepancy may be due to the distinct glycan profiles, as complex glycans on NB-RBD may impact immunoreactivity. In conclusion, our study highlights the potential of plant-based systems for rapid diagnostic reagent production during emergencies. However, transient expression systems, while offering shorter timelines, introduce higher heterogeneity in recombinant protein forms, necessitating careful consideration in serological test development., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work has been performed in the context of the “European Union’s Horizon 2020 Research and Innovation Programme” under Grant Agreement 774078 Pharma Factory project ( https://pharmafactory.org/ ). GS-M acknowledges the Spanish Ministry of Science, Innovation, and Universities for FPI fellowship PRE2019-088852. The authors acknowledge the University of Rouen Normandie and the ANR PhaeomAbs PIA Grand défi Biomédicaments for its financial support. Dr. Marie-Laure Walet-Balieu from Université de Rouen Normandie, INSERM US 51, CNRS UAR 2026, HeRacLeS-PISSARO, F-76000 Rouen, France, is acknowledged for technical help with the injections in LC-ESI MS MS. HeRacLeS PISSARO Proteomics Platform was supported by Rouen University, INSERM, Normandy Region and the European Union. Europe gets involved in Normandy with European Regional Development Fund (ERDF). We thank the excellent technical assistance of Jaana Rikkinen and Kaisa Rinta-Harri at VTT.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Unexpected synergistic HIV neutralization by a triple microbicide produced in rice endosperm

  • Vamvaka, Evangelia
  • Farré Martinez, Gemma
  • Molinos-Albert, Luis M.
  • Evans, Abbey
  • Canela Xandri, Anna
  • Twyman, Richard M.
  • Carrillo, Jorge
  • Ordóñez, Raziel Antonio
  • Shattock, Robin J.
  • O’Keef, Barry R.
  • Clotet, Bonaventura
  • Blanco, Julian
  • Khush, Gurdev S.
  • Christou, Paul
  • Capell Capell, Teresa
The transmission of HIV can be prevented by the application of neutralizing monoclonal antibodies and lectins. Traditional recombinant protein manufacturing platforms lack sufficient capacity and are too expensive for developing countries, which suffer the greatest disease burden. Plants offer an inexpensive and scalable alternative manufacturing platform that can produce multiple components in a single plant, which is important because multiple components are required to avoid the rapid emergence of HIV-1 strains resistant to single microbicides. Furthermore, crude extracts can be used directly for prophylaxis to avoid the massive costs of downstream processing and purification. We investigated whether rice could simultaneously produce three functional HIV-neutralizing proteins (the monoclonal antibody 2G12, and the lectins griffithsin and cyanovirin-N). Preliminary in vitro tests showed that the cocktail of three proteins bound to gp120 and achieved HIV-1 neutralization. Remarkably, when we mixed the components with crude extracts of wild-type rice endosperm, we observed enhanced binding to gp120 in vitro and synergistic neutralization when all three components were present. Extracts of transgenic plants expressing all three proteins also showed enhanced in vitro binding to gp120 and synergistic HIV-1 neutralization. Fractionation of the rice extracts suggested that the enhanced gp120 binding was dependent on rice proteins, primarily the globulin fraction. Therefore, the production of HIV-1 microbicides in rice may not only reduce costs compared to traditional platforms but may also provide functional benefits in terms of microbicidal potency., We thank Ms. Jennifer Wilson for technical assistance with live-virus anti-HIV assays. We received funding from Spanish Ministry of Science and Innovation Grant BIO2014-54426-P; Spanish Ministry of Economy, Industry and Competitiveness Grant AGL2017-85377-R; the European Fund for Economic and Regional Development; Generalitat de Catalunya Grant 2017 SGR 828 to the Agricultural Biotechnology and Bioeconomy Unit; and European Union Farma-Factory Grant Agreement 774078, H2020-BB-2016-2017/H2020-BB-2017-1. This project was funded in whole or in part with federal funds from the National Cancer Institute (NCI), NIH, under Contract HHSN26120080001E and was supported in part by the Intramural Research Program of the NIH, NCI, Center for Cancer Research, and Instituto de Salud Carlos III project PI14/01307. The EVA648 W61D and gp120 0607 IIIB were provided by the Medical Research Center Centralized Facility for AIDS reagents. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does the mention of trade names, commercial products, or organizations imply endorsement by the US government.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A replicating viral vector greatly enhances accumulation of helical virus-like particles in plants

  • Thuenemann, Eva|||0000-0002-9083-2593
  • Byrne, Matthew J.
  • Peyret, Hadrien|||0000-0002-7808-5089
  • Saunders, Keith|||0000-0002-5606-9627
  • Castells-Graells, Roger|||0000-0002-3985-6194
  • Ferriol, Inmaculada|||0000-0003-0111-7537
  • Santoni, Mattia|||0000-0001-5694-7605
  • Steele, John F. C.|||0000-0002-4388-4956
  • Ranson, Neil
  • Avesani, Linda|||0000-0003-4007-7013
  • Lopez-Moya, Juan Jose|||0000-0002-3176-9651
  • Lomonossoff, George|||0000-0003-0700-906X
The production of plant helical virus-like particles (VLPs) via plant-based expression has been problematic with previous studies suggesting that an RNA scaffold may be necessary for their efficient production. To examine this, we compared the accumulation of VLPs from two potexviruses, papaya mosaic virus and alternanthera mosaic virus (AltMV), when the coat proteins were expressed from a replicating potato virus X-based vector (pEff) and a non-replicating vector (pEAQ-HT). Significantly greater quantities of VLPs could be purified when pEff was used. The pEff system was also very efficient at producing VLPs of helical viruses from different virus families. Examination of the RNA content of AltMV and tobacco mosaic virus VLPs produced from pEff revealed the presence of vector-derived RNA sequences, suggesting that the replicating RNA acts as a scaffold for VLP assembly. Cryo-EM analysis of the AltMV VLPs showed they had a structure very similar to that of authentic potexvirus particles. Thus, we conclude that vectors generating replicating forms of RNA, such as pEff, are very efficient for producing helical VLPs.